Under special permit by Viral Genetics.

One blocks a definite survival technique that tumor cells make use of. The other neutralizes a significant growth factor for many tumors. We were holding chosen, partly, because this treatment could be quickly taken to market following a successful physician’s trial and completion of the FDA approval process. Cancer cells use available glucose at an extremely high rate so when stressed by chemotherapy or radiation will selectively burn fat to survive. Some of the mechanisms tumor cells use to meet up their energy demands are unique and so are not used by normal cells. Viral Genetics’ treatment targets those cells by provoking enough energy deficiency to result in tumor cell loss of life.The median duration of follow-up to the last follow-up death or contact was 40.0 years among all 245 subjects and 39.5 years among the 150 subjects with incident cases of epilepsy. The joint ethics examine committee of the University of Turku Medical College and University Medical center of Turku approved the study design. Data on autopsies performed for forensic or clinical reasons, or both, were available for this study. The autopsy price was 70 percent for all deaths in the cohort and 80 percent for incident cases. Total autopsies of most organs had been performed, although in several subjects, a less detailed forensic autopsy was performed. The total results of toxicologic screening were obtained in every subjects.